PGE2 K018-C, K018-H, K018-HX Series Discontinued: New K051-H Available

The hugely popular K018 series of PGE2 Immunoassays, sold since 2010, has been discontinued as of June 1, 2015, and replaced with K051-H, PGE2 Multi-Format EIA Kit, for measurement of PGE2.  The 2014 launched DetectX® PGE2 EIA kit, K051-H1 and K051-H5, uses an internally developed monoclonal to PGE2.  The antibody, which drives the performance of the assays, has remarkable properties.  The assay can handle all the formats and sensitivities of our K018-H, K018-HX and K018-C kits.

  • Lower enhanced cross-reactivity to PGE1, PGF2a, and TXB2

  • Sample volume changes from 25µL to 100µL adjusts the assay sensitivity to cover all PGE2 samples

  • Mouse serum and plasma do not need to be extracted

  • Rapid antibody kinetics allows the same standard curve with a 2 hour room temperature incubation or overnight at 4˚C


The following is a list of citations using the K018 series of PGE2 kits, showing the success Arbor Assays has in developing high quality assay kits.

PGE2 Chemiluminescent CLIA Kit, K018-C –

• “MDMA Increases Excitability in the Dentate Gyrus: Role of 5HT2A Receptor Induced PGE2 Signaling” (15 December 2015)

• “Amelioration of cisplatin-induced mouse renal lesions by a cyclooxygenase (COX)-2 selective inhibitor” (04 June 2013)

• “Ibuprofen Inhibits Colitis-Induced Overexpression of Tumor- Related Rac1b” (26 January 2013)


PGE2 EIA High Sensitivity EIA Kit, K018-HX –

• “Novel 2-phenyl-4,5,6,7-tetrahydro[b]benzothiophene analogues as selective COX-2 inhibitors: Design, synthesis, anti-inflammatory evaluation, and molecular docking studies” (08 March 2017)

• “The Effect of Non-Steroidal Anti-Inflammatory Drugs on Canine Transitional Cell Carcinoma and Its Correlation with Cyclooxygenase-2 Expression” (21 May 2015)

• “Verbascoside down-regulates some pro-inflammatory signal transduction pathways by increasing the activity of tyrosine phosphatase SHP-1 in the U937 cell line” (21 March 2015)

“COX-2 dependent regulation of mechanotransduction in human breast cancer cells” (20 February 2015)

• “Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells” (18 November 2014)

• “The Role of Integrin αVβ3 in Osteocyte Mechanotransduction” (10 November 2014)

• “In vitro enantioselective pharmacodynamics of Carprofen and Flunixin-meglumine in feedlot cattle” (25 April 2013)

• “Microglia Are Essential to Masculinization of Brain and Behavior” (13 February 2013)

• “The mitochondrial citrate carrier: a new player in inflammation.” (15 September 2011)

• “Brain IL-6- and PG-dependent actions of IL-1β and lipopolysaccharide in avian fever.” (11 September 2011)


PGE2 EIA Kit, K018-H –

• “Dendritic cells differentiated from human umbilical cord blood-derived monocytes exhibit tolerogenic characteristics” (23 July 2015)

• “Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats” (17 July 2015)

• “Pomegranate inhibits neuroinflammation and amyloidogenesis in IL-1β-stimulated SK-N-SH cells” (10 July 2015)

• “Cyclooxygenase-2 Suppresses the Anabolic Response to PTH Infusion in Mice” (17 March 2015)

• “Hepatic cyclooxygenase-2 expression protects against diet-induced steatosis, obesity and insulin resistance” (24 Novembe 2014)

• “Tiliroside, a dietary glycosidic flavonoid inhibits TRAF-6/NF-κB/p38-mediated neuroinflammation in activated BV2 microglia” (23 August 2014)

• “Sustained Release of Prostaglandin E2 in Fibroblasts Expressing Ectopically Cyclooxygenase 2 Impairs P2Y-Dependent Ca2+-Mobilization” (18 August 2014)

• “Inflammatory suppressive effect of prostate cancer cells with prolonged exposure to transforming growth factor β on macrophage‑differentiated cells via downregulation of prostaglandin E2” (01 August 2014)

• “A key role of the mitochondrial citrate carrier (SLC25A1) in TNFα- and IFNγ-triggered inflammation” (27 July 2014)

• “Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells” (15 July 2014)

• “Effects of Momordica charantia on Serum Lipid Profile, Serum Protein Levels and Selected Markers of Cardiovascular Damage in Diabetic Rats” (01 April 2014)

• “Picralima nitida seeds suppress PGE2 production by interfering with multiple signalling pathways in IL-1β-stimulated SK-N-SH neuronal cells” (31 January 2014)

• “CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes” (31 January 2014)

• “Progression of liver oncogenesis in the double transgenic mice c-myc/TGF is not enhanced by cyclooxygenase-2 expression” (01 October 2013)

• “Targeting the EP1 receptor reduces fas ligand expression and increases the anti-tumor immune response in an in vivo model of colon cancer” (02 February 2013)

• “Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells” (30 November 2012)

• “Blood hsCRP And PGE2 Content With Clinical Outcome Using Modified Fenestratio- Restorative Spinoplasty Better Than Lamonectomy-Fusion In Lumbar Stenosis” (01 November 2012)

• “Mesenchymal Stem Cells Repress Th17 Molecular Program through the PD-1 Pathway” (17 September 2012)

• “Effects of lipoic acid on lipolysis in 3T3-L1 adipocytes” (31 August 2012)

• “Ethanolic Leaf Extract of Croton Zambesicus (MÜll. Arg.) Improves Gastric Emptying Capacity and Gastric Mucosa Integrity in Streptozotocin-induced Diabetic Rats” (04 April 2012)

• “Nuclear factor-kappaB (NF-kappaB) mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase. ” (09 September 2009)


Subscribe to our mailing list

Sign up to our e-mail newsletter and receive updates and special offers.